Candel Therapeutics, Inc. — Form 8-K Summary
Reporting date: February 22, 2023. This Current Report was furnished under Item 7.01, Regulation FD Disclosure.
Business Context and Reporting Period
Candel Therapeutics is evaluating CAN-2409 in a randomized, double-blind, placebo-controlled Phase 2 clinical trial (NCT02768363) involving patients with low-to-intermediate-risk, localized, non-metastatic prostate cancer undergoing active surveillance.
- The trial is fully enrolled with 187 patients.
- The active-to-placebo allocation is 2:1.
Key Financial Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material Changes Versus Prior Expectations
The Company changed the trial’s primary endpoint to biopsy-proven progression-free survival. Progression is defined as an increase in Gleason grade or an increase in tumor volume to more than 33%.
Because the endpoint is event-driven and requires additional events, the timing of topline results has been delayed. The Company previously guided to topline results in the fourth quarter of 2023 and now anticipates results in the fourth quarter of 2024, based on the current rate of events.
Guidance, Outlook, Risks and Unusual Items
- The revised timing is dependent on accumulating a sufficient number of progression or death events before trial unblinding.
- The Company stated that additional follow-up is required to detect a reduction in the hazard for progression or death.
- The projected fourth-quarter 2024 timing is current management guidance and may change based on the rate of events.
- The disclosure was furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act, except where expressly incorporated by reference.
Investor Verification Items
- Confirm the updated primary endpoint definition and statistical analysis plan.
- Monitor event accumulation and whether topline results remain expected in the fourth quarter of 2024.
- Verify the eventual efficacy and safety results for the 187-patient trial.
- Review subsequent filings for financing needs, cash runway, and other financial information not included in this Form 8-K.